Skip to main content
Fig. 2 | Translational Medicine Communications

Fig. 2

From: Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines

Fig. 2

Characterization of vemurafenib and/or cobimetinib-resistant melanoma cell lines. A Cell invasion ability of SAN, SAN-VR, SAN-CR and SAN-VRCR cell lines evaluated by Transwell invasion assay after 48 h in basal condition. B Cell invasion ability of A375, A375-VR, A375-CR and A375-VRCR cell lines evaluated by Transwell invasion after 48 h in basal condition. C, D Wound healing assays performed to detect migration ability of C SAN, SAN-VR, SAN-CR and SAN-VRCR cell lines and D A375, A375-VR, A375-CR and A375-VRCR cell lines after 48 h of culture. * <0,05. **: P < 0.001; ****: P < 0,0001

Back to article page